Abbott Laboratories (ABT)vsIradimed Co (IRMD)
ABT
Abbott Laboratories
$91.07
-1.64%
HEALTHCARE · Cap: $151.49B
IRMD
Iradimed Co
$93.07
-0.53%
HEALTHCARE · Cap: $1.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 52210% more annual revenue ($45.13B vs $86.28M). IRMD leads profitability with a 27.4% profit margin vs 13.9%. ABT appears more attractively valued with a PEG of 1.30. IRMD earns a higher WallStSmart Score of 61/100 (C+).
ABT
Buy56
out of 100
Grade: C
IRMD
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.5%
Fair Value
$70.89
Current Price
$91.07
$20.18 premium
Intrinsic value data unavailable for IRMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 32.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Keeps 27 of every $100 in revenue as profit
Earnings expanding 22.1% YoY
Areas to Watch
Earnings declined 19.7%
Trading at 12.1x book value
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.
Bull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 32.9%. Revenue growth of 12.6% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are EPS Growth.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Market Cap, Piotroski F-Score. A P/E of 50.3x leaves little room for execution misses.
Key Dynamics to Monitor
ABT profiles as a value stock while IRMD is a mature play — different risk/reward profiles.
IRMD carries more volatility with a beta of 0.91 — expect wider price swings.
IRMD is growing revenue faster at 12.6% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Bottom Line
IRMD scores higher overall (61/100 vs 56/100), backed by strong 27.4% margins and 12.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?